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The theophylline-enoxacin interaction: 
I. Effect of enoxacin dose size on 
theophylline disposition 
Theophylline interacts pharmacokinetically with a variety of other drugs. Recently enoxacin was found 
to change theophylline's disposition. In a four-subject, four-way crossover study enoxacin was 
administered every 12 hours at four levels (0, 25, 100, and 400 mg) for 14 doses. With the ninth dose 
of enoxacin, 200 mg theophylline was coadministered. Blood and urine samples were assayed by sensitive 
and specific assays for the parent drugs and their metabolites. Significant reduction in the formation of 
theophylline's three major metabolites occurred on coadministration of enoxacin. At the 400 mg dose 
level, enoxacin caused a threefold decrease in theophylline's plasma clearance, a fourfold decrease in the 
urinary recovery of 3-methylxanthine and 1, 3-dimethylurate, and a threefold decrease in the recovery of 
1-methylurate. (CLIN PHARMACOL THEk 1988;44:579-87.) 
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Theophylline has been used extensively for many 
years in the treatment of chronic obstructive pulmonary 
disease. Because it has a realtively narrow therapeutic 
index, theophylline can readily cause a variety of un- 
pleasant and serious side effects.' Countless factors 
have been implicated in the development of theophyl- 
line toxicity (e.g., age, smoking habits, underlying dis- 
ease, and concomitant drug use.)2 In virtually all of the 
studies conducted on such factors a shift in some defined 
pharmacokinetic parameter explained the development 
of toxicity. 
Theophylline's primary route of elimination in hu- 
mans is through hepatic metabolism. Tang-Liu et al.' 
reported that up to 80% of an administered dose 
of theophylline was eliminated via metabolic trans- 
formation. They reported mean urinary recoveries 
of theophylline and its three major metabolites, 
3-methylxanthine (3 -MX) , 1 - methylurate (1-MU) , and 
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1 ,3-dimethylurate (1,3-MU), to be 13.3%, 15.7%, 
19.8%, and 39.1%, respectively, after an intravenous 
theophylline dose. When an oral dose of theophylline 
was administered to the subjects, mean urinary recov- 
eries for theophylline, 3-MX, 1-MU, and 1,3-MU were 
found to be 13.8%, 13.3%, 15.0%, and 36.2%, re- 
spectively. 
Several drugs are known to alter theophylline dis- 
position by either increasing or suppressing its rate of 
metabolism.4-7 Landay et al.4 reported a mean increase 
in theophylline's total clearance of 34% when each of 
six healthy subjects was pretreated with phenobarbital 
for 4 weeks. Boyce et al.' reported that concurrent use 
of rifampin increased mean total theophylline clearance 
by 40% in 10 subjects. Conversely, cimetidine, oral 
contraceptives, and propranolol have been reported to 
significantly decrease total theophylline clearance.6-8 It 
is unlikely that changes in plasma protein binding play 
any significant role in each interaction, because the- 
ophylline is only 52.6% to 65% bound.9'° Furthermore, 
in none of the studies cited above did the apparent 
distribution volume of theophylline change. Presum- 
ably, each of these drug interactions could be explained 
by induction or suppression of one or more of the known 
major theophylline metabolic pathways. 
Recently theophylline has been found to interact 
pharmacokinetically with the azaquinoline antiinfective 
agent, enoxacin. Wijnands et al." reported that eight 
of 10 patients receiving theophylline developed nausea 
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Mean plasma concentration (mg I L) and SD* 
Numbers in parentheses are SDs. 
*Plasma concentrations less than 0.2 mg/L for theophylline and 0.02 mg/L for each metabolite were reported as zero. 
and vomiting when enoxacin was added to the drug 
regimen. They found no changes in either plasma pro- 
tein binding or renal clearance of theophylline when 
enoxacin was coadministered. Maesen et al.'2 also 
found an unusually high rate of theophylline-like tox- 
icity in 12 of 15 patients receiving enoxacin. Side ef- 
fects included nausea (n = 9), vomiting (n 1), epi- 
leptiform attack (n = I), dizziness (n = 2), halluci- 
nations (n 1), and depersonalization (n = 1). Three 
subjects received enoxacin and theophylline concur- 
rently without reporting side effects. However, 10 of 
the 12 subjects who had side effects were receiving 
theophylline concurrently. Wijnands et al.13 conducted 
a follow-up study after their initial observations and 
reported that enoxacin (800 to 1200 mg / day) induced 
a 2.6-fold increase in mean trough theophylline plasma 
concentrations in 14 subjects. With these observations 
in mind, we examined the relationship between the size 
of the enoxacin dose and plasma concentrations and 
urinary excretion of theophylline and its metabolites 
3-MX, 1-MU, and 1,3-MU. 
METHODS 
Study design. The study had a four-subject, four- 
way crossover design. Each subject received a single 
200 mg dose of theophylline during each of four dif- 
ferent enoxacin treatments. The control treatment (A) 
and treatments B, C, and D corresponded to enoxacin 
doses of 0, 25, 100, and 400 mg every 12 hours, re- 
spectively. Each treatment consisted of oral adminis- 
tration of an enoxacin capsule twice daily for 14 doses. 
With the administration of the ninth enoxacin dose, 200 
mg theophylline (as Theo-Dur) was administered to 
each subject. Enoxacin and its major metabolite (the 
enoxacin-oxo-metabolite), theophylline, 3-MX, 1-MU, 
and 1,3-MU concentrations were monitored in plasma 
and urine during the 72-hour period after each theoph- 
ylline dose. 
Time 
(hr) 
Theophylline 3-MX 
A B C D A 
0 0 0 0 0 0 0 0 0 
1 0.462 0.679 0.373 0.326 0.0418 0 0.0132 0.0127 
(0.362) (0.425) (0.283) (0.0974) (0.0835) (0.0264) (0.0147) 
2 0.943 1.01 0.935 0.859 0.0485 0.104 0.0352 0 
(0.403) (0.508) (0.357) (0.437) (0.0739) (0.0666) (0.0431) 
4 1.51 1.96 1.35 1.49 0.0802 0.169 0.108 0 
(0.270) (0.803) (0.378) (0.320) (0.0696) (0.125) (0.0975) 
6 2.55 2.77 2.82 3.26 0.101 0.177 0.143 0 
(0.729) (1.07) (0.817) (1.19) (0.0849) (0.109) (0.105) 
7 2.67 3.20 3.39 3.30 0.147 0.188 0.123 0 
(0.792) (0.820) (0.973) (1.37) (0.129) (0.0962) (0.0893) 
8 2.50 3.37 3.82 3.46 0.187 0.155 0.0978 0 
(0.941) (0.558) (1.06) (1.18) (0.0632) (0.0846) (0.0772) 
10 2.53 3.35 3.70 3.79 0.200 0.164 0.0897 0 
(1.07) (0.555) (0.565) (0.956) (0.0471) (0.0953) (0.0698) 
12 2.05 2.68 3.30 3.78 0.134 0.161 0 0 
(0.909) (1.14) (0.516) (0.634) (0.0529) (0.103) 
24 0.749 1.23 2.00 2.79 0.0897 0.0517 0 0 
(0.573) (0.428) (0.478) (0.741) (0.0913) (0.0708) 
30 0.385 0.945 1.47 2.03 0.0488 0.0390 0 0 
(0.326) (0.512) (0.366) (0.787) (0.0674) (0.0525) 
36 0 0.427 0.933 1.60 0.0285 0.0146 0.0253 0 
(0.348) (0.368) (0.702) (0.0570) (0.0292) (0.0505) 
48 0 0 0.407 0 0 0 0.0221 0 
(0.379) (0.0441) 
54 0 0 0.289 0 0 0 0 0 
(0.239) 
72 0 0 0 0 0 0 0 0 
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Table I. Mean plasma concentrations of theophylline and its three major metabolites 
The four subjects who participated in the study were 
healthy, male, nonsmoking volunteers. Their ages 
ranged from 22 to 27 years (mean 251/2 years) and their 
weights from 156 to 180 pounds (mean 164 pounds). 
Each subject gave written, informed consent to partic- 
ipate in the study and each subject had normal vital 
signs and laboratory screening parameters. All subjects 
adhered to a strict xanthine-free diet beginning 3 days 
before the first enoxacin dose and extending for 3 days 
after the single theophylline dose. 
Blood sampling consisted of drawing 7 ml samples 
from a forearm vein with heparinized vacutainers. The 
samples were drawn at 0 ( just before the theophylline 
dose) and 1, 2, 4, 6, 7, 8, 10, 12, 24, 30, 36, 48, 54, 
and 72 hours after theophylline dose. The plasma was 
immediately separated from the sample, quick frozen, 
and stored at - 20° C until assayed. 
Just before theophylline administration, each subject 
voided all urine. Urine was then collected during the 
following intervals: 0 to 2, 2 to 6, 6 to 8, 8 to 12, 12 
Mean plasma concentration (mgl L) and SD* 
to 24, 24 to 48, and 48 to 72 hours. The urine volumes 
from each collection period were measured and re- 
corded; a 10 ml aliquot of each collection was kept for 
assays. Each aliquot was immediately frozen and stored 
at - 20° C until assayed. All plasma and urine samples 
were assayed for parent drugs and metabolites within 
2 weeks. 
Analysis.The HPLC assay methods for determining 
theophylline, 3-MX, 1-MU, and 1,3-MU concentra- 
tions in plasma and urine were modifications of those 
developed by Tang-Liu et al.3 The HPLC apparatus 
consisted of a Waters 501 solvent delivery pump (Wa- 
ters Associates, Milford, Mass.) in series with a Waters 
WISP 710B injector. The main column was a Beckman 
C18, Ultrasphere ODS, 5 p.m, 4.6 mm by 250 mm 
(Beckman Instruments, Inc., Fullerton, Calif.). It was 
water jacketed (model T-2, Lauda RC3, Brinkmann 
Instruments, Inc., Westbury, N.Y.) and kept at a con- 
stant temperature of 25° C. Detection of the analytes 
was accomplished with a Waters model 440 ultraviolet 
1-MU 1,3-MU 
A B C D A 
0 0 0 0 0 0 0 0 
0.0249 0 0 0.114 0.233 0 0 0 
(0.0295) (0.229) (0.356) 
0 0.0720 0.0384 0.0501 0.459 0.0246 0 0 
(0.0381) (0.241) (0.0329) (0.0710) (0.791) 
0.0822 0.230 0.0431 0.0355 0.575 0 0 0 
(0.0381) (0.241) (0.0329) (0.0710) (0.791) 
0.144 0.328 0.147 0.0232 0.587 0.160 0 0 
(0.119) (0.297) (0.181) (0.0464) (0.628) (0.104) 
0.101 0.312 0.0872 0.0189 0.536 0.153 0 0 
(0.0815) (0.240) (0.0533) (0.0379) (0.515) (0.0917) 
0.0895 0.292 0.0815 0.0250 0.377 0.136 0.0327 0 
(0.0526) (0.237) (0.0461) (0.0500) (0.286) (0.0866) (0.0337) 
0.0897 0.354 0.122 0.0778 0.493 0.139 0 0 
(0.0749) (0.293) (0.121) (0.0930) (0.241) (0.0745) 
0.0873 0.351 0.0416 0.0270 0.198 0 0 0 
(0.0743) (0.313) (0.0334) (0.0540) (0.168) 
0.0380 0.239 0.0255 0 0.0862 0 0.0325 0 
(0.0458) (0.207) (0.0259) (0.0608) (0.0344) 
0.0236 0.192 0.0116 0 0.0396 0.0603 0 0 
(0.0473) (0.213) (0.0233) (0.0457) (0.0449) 
0.0117 0.0868 0.0671 0 0.0207 0.0334 0 0 
(0.0233) (0.158) (0.0848) (0.0273) (0.0394) 
0 0 0.0458 0 0 0 0 0 
(0.0763) 
0 0 0.0263 0 0 0 0 0 
(0.0525) 
0 0 0 0 0 0 0 0 
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Table II. Theophylline pharmacokinetic parameters 
Mean parameter value after indicated treatment 
Numbers in parentheses are SDs. 
*Significance of difference among treatment mean squares of the ANOVA for crossover design. 
tPower of the ANOVA (the probability of detecting the difference in treatment means). 
detector set at 280 nm. The ultraviolet absorption re- 
sponse was traced by a Linear recorder (Linear Instru- 
ments Corp., Reno, Nev.). The mobile phase consisted 
of methanol mixed with a solution of 10 mmol/L so- 
dium acetate and 5 mmol/L tetrabutylammonium hy- 
drogen sulfate adjusted to pH 4.75 with glacial acetic 
acid or 1 mol/L sodium hydroxide. The ratio of meth- 
anol to aqueous buffer was 12/88, vol/ vol; the flow 
rate was 1.4 ml / min. 
Plasma samples were prepared for analysis by first 
transferring 0.5 ml plasma to a 7 ml glass culture tube 
(13 mm by 100 mm) To each sample was added 2 ml 
acetonitrile containing 2.5 Rg/m1 of internal standard 
(13-hydroxyethy1theophylline). The mixture was vor- 
texed for 20 seconds and then centrifuged at 2000 g for 
10 minutes to sediment the precipitated protein. The 
supernatant was then transferred to a 10 ml glass culture 
tube (16 mm by 100 mm) and vortexed in a Haake 
Buehler vortex evaporator (Haake Inc., Saddle Brook, 
N.J.) at 40° C for 40 minutes. The remaining solution 
was then centrifuged for 4 minutes at 12,800 g in an 
Eppendorf microcentrifuge (Brinkmann). A 50 ill vol- 
ume of supernatant was injected via the WISP onto the 
HPLC column. Theophylline plasma concentrations 
were monitored over the range of 0.200 mg/ L to 10.0 
mg / L; 3-MX, 1-MU, and 1,3-MU plasma concentra- 
tions were monitored over the range of 0.0200 mg/ L 
to 1 mg/L. 
Urine samples were prepared for injection by adding 
0.5 ml urine to 0.5 ml 0.1 mol/L tetrabutylammonium 
hydrogen sulfate and 0.25 ml carbonate buffer in a 
screw-capped centrifuge tube. The carbonate buffer (pH 
11) was prepared by mixing a 0.1 mol/L sodium car- 
bonate solution with a 0.1 mol/L sodium bicarbonate 
solution in a 9/1, vol/vol ratio. The solution of urine, 
ion-pairing agent, and buffer were vortexed for 10 sec- 
onds followed by the addition of 1 gm ammonium sul- 
fate. The mixture was vortexed again for 30 seconds. 
To the mixture was added 10 ml extraction solvent 
(ethyl acetate, chloroform, isopropanol, 45/45/10, 
vol/ vol/ vol, and B-hydroxyethyltheophylline, 7.5 
mg/L). The mixture was vortexed for 1 minute followed 
by centrifugation for 10 minutes at 2000 g. To a glass 
culture tube (16 mm by 100 mm) was added 5 ml of 
the upper organic layer. In a 40° C water bath and under 
a gentle stream of nitrogen, the organic solution was 
evaporated to dryness. The residue was then reconsti- 
tuted with 1 ml of a 50 mmol/ L tetrabutylammonium 
hydrogen sulfate! 10 mmol/ L sodium acetate! 10% 
methanol (vol/ vol! vol) solution. To ensure maximum 
dissolution of the analytes, the tubes were vortexed for 
30 seconds; 50 Ill of the reconstituted solution was then 
injected onto the column. Theophylline and its three 
major metabolites were monitored over a concentration 
range of 1 to 100 mg/L. 
The assay method employed to determine enoxacin 
and the enoxacin-oxo-metabolite in plasma and urine 
used the same HPLC system as that used for theoph- 
ylline assays. The only differences were that a Beckman 
C, column was used (all column dimensions were 
similar) and ultraviolet detection was performed at 
340 nm. The mobile phase consisted of a 1 mmol/L 
1-pentanesulfonic acid solution, adjusted to a pH of 2.5 
with concentrated phosphoric acid, and ethanol in a 
ratio of 65/35, vol / vol. The flow rate was set at 0.7 
ml/ min. 
Plasma samples were prepared for injection by 
mixing 1 ml plasma with 1 ml 5% trichloroacetic 
acid/ acetonitrile (1/1, vol/vol) in a 16 mm by 100 nun 
glass culture tube. Each sample mixture was vortexed 
for 20 seconds and allowed to sit for 20 minutes. Sam- 
ples were vortexed again for 5 seconds and 1.5 ml of 
each was spun in an Eppendorf centrifuge at 12,800 g 
for 10 minutes. Exactly 20 Ill supernatant was then 
Parameter A B C D p Value* 1 - 
AUC (mg hr/L) 44.2 (24.2) 62.9 (14.2) 88.8 (23.9) 121 (50) 0.0001 >0.99 
Oral clearance (ml! mm) 117 (107) 55.1 (12.6) 39.3 (9.0) 31.1 (12.3) 0.161 0.35 
Cmx (mg/L) 2.81 (0.84) 3.65 (0.55) 4.00 (0.85) 4.02 (0.84) 0.004 0.97 
(hr) 8.00 (2.31) 7.75 (1.71) 9.00 (1.15) 10.3 (2.36) - - (hr') 0.0919 (0.0184) 0.0788 (0.0353) 0.0535 (0.010) 0.0680 (0.0475) 0.453 <0.2 
Elimination ti (hr) 7.78 (1.66) 10.5 (5.19) 13.5 (2.52) 14.2 (8.55) - 
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Table III. Mean AUCs 
AUC (mg hr/ L) 
injected onto the column via the WISP. Concentrations 
of enoxacin were monitored over a range of 0.10 to 10 
mg /L; the oxo-metabolite was monitored over a range 
of 0.20 to 2 mg /L. 
Urine samples were prepared by initially diluting 
each twentyfold with double-distilled, deionized water. 
To 1 ml of the diluted urine was added 2 ml of ethyl 
acetate in a 16 mm by 100 mm glass culture tube. The 
sample was then vortexed for 30 seconds and centri- 
fuged at 2000 g for 10 minutes. The upper organic layer 
was removed and 10 pA of the remaining aqueous layer 
could then be injected onto the column Enoxacin was 
monitored over a concentration range of 5 to 200 
mg /L; the oxo-metabolite was monitored over a range 
of 1 to 40mg / L. 
Assay sensitivity and reproducibility. The lowest con- 
centration on the plasma standard curves was 0.2 
mg/ L plasma for theophylline and 0.02 mg/ L plasma 
for each theophylline metabolite. The lowest concen- 
tration on the plasma standard curves was 0.100 
mg / L plasma for enoxacin and 0.200 mg/ L for the 
enoxacinoxo-metabolite. Corresponding concentrations 
for urine were 1 mg / L for theophylline and each the- 
ophylline metabolite, 2 mg /L for enoxacin, and 2 
mg / L for the enoxacin-oxo-metabolite. These concen- 
trations were considered to be the assay sensitivities 
and all concentrations measured below these values 
were taken as zero. 
Each assay was validated by measuring the concen- 
tration of five to seven samples of each of these different 
concentrations on each of 3 different days. Plasma con- 
centrations used for theophylline were 0.200, 1.00, 
5.00, 10.0, and 20.0 mg/L, those for each theophylline 
metabolite were 0.0500, 0.100, 0.500, 1.00, and 2.00 
mg / L, those for enoxacin were 0.25, 0.500, 1.00, 
2.50, 5.00, 7.50, and 10 mg /L, and those for the 
enoxacin-oxo-metabolite were 0.05, 0.100, 0.200, 
0.500, 1.00, 1.50, and 2.0 mg/L. During analysis of 
study plasma and urine samples quality control samples 
were also analyzed along with the unknowns. 
Numbers in parentheses are SDs. 
*Significance of difference among treatment mean squares of the ANOVA for crossover design. 
tPower of the ANOVA (probability of detecting the difference in treatment means). 
Pharmacokinetic analysis. Oral clearance (CL/F) of 
theophylline was calculated as dose/ AUC. The bio- 
availability (F) could not be estimated because some 
metabolites of theophylline were not measurable 
because they are unknown. First-order elimination 
rate constants (le) were estimated by least-squares 
linear regression of the terminal log-linear plasma- 
concentration-time data. The plasma elimination half- 
life (t112) was determined by dividing ke into 0.693. To 
estimate the AUC the trapezoidal rule was employed. 
Molar fraction-recovered values were estimated by con- 
verting each amount recovered in urine into molar 
equivalents and then dividing those numbers by the 
molar amount of theophylline dosed to each subject. 
The molecular weights of theophylline, 3-MX, 1-MU, 
and 1,3-MU are 180.2, 166.1, 182.1, and 196.2, re- 
spectively. If it is assumed that Theo-Dur is 100% bio- 
available, each subject should have absorbed 200 mg 
theophylline (1.11 mmol/L). Renal clearances were 
estimated by dividing the amount of compound recov- 
ered in urine during each 12-hour time period by the 
compound's respective plasma AUC during the same 
time period. 
Statistical analysis. The 27 assay values (three con- 
centrations for 3 days for three replicates) for each 
compound, expressed as a percent of the known and 
obtained during assay validation, were analyzed by two- 
factor ANOVA in which mean squares were calculated 
for concentrations, days, and error. 
The 16 values (four subjects given four enoxacin 
doses) for each measured quantity or parameter were 
analyzed by ANOVA for crossover design' in which 
mean squares were calculated for subjects, treatments, 
time periods, and residual. The significance levels 
(p values) of the treatment mean squares are listed in 
Tables II, III, and IV. In addition, the power of the 
ANOVA, 1 0, was calculated 14 in each case and 
these values are listed in Tables II, III, and IV also. 
The 1 13 values are the probabilities of detecting at 
a = 0.05 the differences in means observed. 
Metabolite A p Value* 1 pt 
3-MX 3.15 (2.48) 2.84 (1.84) 2.18 (2.66) 0.300 (0.288) 0.221 0.29 
1-MU 1.83 (1.56) 8.32 (7.50) 2.33 (1.73) 0.290 (0.534) 0.138 0.40 
1,3-MU 7.31 (2.95) 3.30 (2.16) 0.787 (1.12) 0 (0) 0.016 0.83 
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Table IV. Mean amounts of theophylline and its three major metabolites excreted in urine in the 72-hour 
sampling period 
Mean amount excreted after indicated treatment (mg) 
Numbers in parentheses are SDs. 
*Significance of difference among treatment mean squares of the ANOVA for crossover design. 
tPower of the ANOVA (probability of detecting the difference in treatment means). 
Table V. Mean plasma concentrations of enoxacin and its oxo-metabolite 
RESULTS 
Assay reproducibility. In each two-factor ANOVA of 
the plasma assay validation data for theophylline and 
its three metabolites none of the mean squares for con- 
centrations (expressed as a percentage of the known 
concentrations) and days were significant. Coefficients 
of variation calculated from the root mean square errors 
were 5.02%, 4.51%, 5.56%, and 5.15% for theoph- 
ylline 3-MX, 1-MU, and 1,3-MU, respectively. Co- 
efficients of variation calculated from the pooled 27 
values for each compound were 4.85%, 4.85%, 5.62%, 
and 5.23%, respectively, for the compounds in the same 
order. Analysis of urinary data gave similar results. 
Assay validation for enoxacin gave coefficients of van- 
CLIN PHARMACOL THER 
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Numbers in parentheses are SDs. 
*Plasma concentrations less than the lowest point on the standard curves, namely 0.10 mg/L for enoxacin and 0.05 mg/L for the oxo-metabolite, were recorded 
as zero. 
tEnoxacin was administered every 12 hours, hence these are times of dosing. 
ation ranging from 2.33% to 6% and validation for the 
enoxacin-oxo-metabolite gave coefficients of variation 
ranging from 4.04% to 5.06%. 
Coefficients of variation estimated from the assay of 
quality control standards at the same time as assay of 
the unknowns were of the same order of magnitude as 
those listed above. 
Theophylline and metabolites. Mean plasma con- 
centrations of theophylline and its three measured me- 
tabolites at each sampling time are listed in Table I. 
Table II lists the mean theophylline pharmacokinetic 
parameters along with the significance levels (p values) 
of the treatment mean squares of the ANOVA for cross- 
over design and the power (1 - 13) values of the 
Time 
(hr) 
Mean plasma concentration (mg/ L)* 
Enoxacin Oxo-metabolite 
0 0.134 (0.0372) 0.594 (0.425) 0 0 0 
1 0.153 (0.0484) 0.471 (0.0423) 1.71 (0.189) 0 0.111 (0.223) 0 
2 0 0.640 (0.229) 1.94 (0.664) 0 0 0.209 (0.160) 
4 0 0.438 (0.208) 1.59 (0.547) 0 0 0.184 (0.128) 
6 0 0.330 (0.187) 1.30 (0.466) 0 0 0.298 (0.0753) 
7 0 0.257 (0.141) 1.00 (0.159) 0 0.0500 (0.100) 0 
8 0 0.226 (0.139) 0.845 (0.320) 0 0 0 
10 0 0.168 (0.0684) 0.693 (0.232) 0 0.0500 (0.100) 0 
12t 0 0.173 (0.156) 0.886 (0.548) 0 0 0 
24t 0 0.191 (0.109) 0.686 (0.491) 0 0.0500 (0.100) 0.0778 (0.156) 
30 0 0.289 (0.137) 1.08 (0.557) 0 0 0.0870 (0.174) 
36t 0 0 0.744 (0.469) 0 0 0.193 (0.135) 
48t 0 0 1.01 (0.606) 0 0 0.206 (0.147) 
54 0 0.241 (0.0987) 1.22 (0.426) 0 0 0 
72t 0 0.179 (0.109) 0.657 (0.515) 0 0 0 
Compound A p Value* I - Pt 
Theophylline 29.2 (12.2) 28.2 (10.7) 48.2 (13.1) 46.1 (13.5) 0.085 0.50 
3-MX 23.4 (22.2) 16.0 (9.8) 35.5 (32.3) 6.31 (4.29) 0.306 0.25 
1-MU 34.9 (22.4) 61.2 (18.0) 45.7 (21.9) 10.4 (6.6) 0.015 0.86 
1,3-MU 99.4 (16.8) 45.9 (23.9) 27.7 (10.1) 26.3 (8.2) 0.0005 >0.99 
ANOVAs. It can be seen that there is a general trend 
in AUC, peak plasma drug concentration (Crnax), time 
to reach peak concentration (L.), and elimination t172 
to increase as the enoxacin dose increases. The differ- 
ences among treatment areas are highly significant 
(p = 0.0001) with very high power (1 - p > 0.99). 
However, the oral clearance, reciprocally related to 
AUC, has ap value of only 0.161, with 1 - 13 = 0.35. 
The increase in AUC of theophylline with increase in 
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THEOPHYLLINE 
ID 3-MX 
1-mu 
1, 3-MU 
enoxacin dose was marginally correlated (r = 0.594). 
However, differences among treatment mean maximum 
plasma concentrations of theophylline were highly sig- 
nificant (p = 0.004) with high power (1 
-13 = 
0.97). Differences among mean elimination rate con- 
stants of theophylline were not significant (p = 0.453). 
Table III lists mean AUCs with the p and 1 - 13 
values. Although there is a trend for the area to decrease 
for each metabolite with an increase in the enoxacin 
y ---- the natural logarithm of the pharmacokinetic parameter (n = 16 in each case) 
Pharmacokinetic parameter 
(mg every 12 hr) p Value 
Urinary recovery of theophylline (mg) 0.458 0.074 
Urinary recovery of 3-MX (mg) 0.476 0.061 
Urinary recovery of 1-MU (mg) 0.724 0.002 
Urinary recovery of 1,3-MU (mg) 0.530 0.034 
Cma, (mg/L) 0.355 0.177 
(hr) 0.453 0.078 
CL / F (ml / min) 0.594 0.0152 
k, 
ti,, (hr) 
0.299 
0.294 
0.260 
0.269 
AUC (mg/L hr) 0.594 0.0152 
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Fig. 1. Mean molar fractions of theophylline and its major metabolites recovered during the 72- 
hour urine collection period. 
Table VI. Correlation coefficients and their significance levels for correlation of x = enoxacin dose and 
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dose, only the differences among treatment means for 
the 1,3-MU metabolite are significant (p = 0.016) with 
high power (1 13 > 0.83). 
Table IV lists the mean amounts of theophylline and 
its metabolites excreted in urine in the 72-hour sampling 
period along with the p and 1 p values. Differences 
among mean amounts of both the 1 = MU (p = 
0.015; 1 13 = 0.86) and the 1,3-MU (p < 0.0005; 
1 13 > 0.99) metabolites are highly significant with 
high power, whereas differences among means of the- 
ophylline and 3-MX have p values greater than 0.05. 
Fig. 1 illustrates the relative change in the mean mole 
fraction of theophylline and its three metabolites re- 
covered in urine for each of the four treatments. 
There were no changes in renal clearance of theoph- 
ylline or its major metabolite when enoxacin was added 
to the dosage regimen. 
Enoxacin and oxo-metabolite. Table V lists the 
mean plasma concentrations of enoxacin and its oxo- 
metabolite at each sampling time. 
Correlations. Table VI lists correlation coefficients 
for linear regressions of x = enoxacin dose and 
y = natural logarithm of a pharmacokinetic parameter, 
where n = 16 in each case. The correlation coefficients 
were significant (p < 0.05) in the cases of urinary re- 
covery of 1-MU, urinary recovery of 1,3-MU, oral 
clearance, and AUC. Logarithmic transformation was 
used because rectilinear plots of the data were curvi- 
linear. Thus, although the differences in mean param- 
eter values sometimes did not achieve significance, the 
data trends were significant as indicated by regression. 
DISCUSSION 
The results of this study indicate that enoxacin exerts 
an effect on theophylline metabolism. This effect ap- 
pears to be a dose-dependent suppression of theoph- 
ylline' s three major metabolic pathways. 
This effect on metabolism is evident by relating the 
enoxacin dose to theophylline's pharmacokinetic pro- 
file. Both the theophylline plasma AUC and Cmax values 
were increased significantly by enoxacin administra- 
tion. There were also general trends in theophylline's 
CL /F and t112 to indicate that the drug's elimination was 
suppressed. There were no changes in renal clearance 
for theophylline or its major metabolites when enoxacin 
was added to the dosage regimen. 
The apparent cause of this change in theophylline 
disposition was suppression of oxidative metabolism. 
The degree of suppression was dependent on the dose 
of enoxacin given. The mean amount of 3-MX recov- 
ered in urine fell almost fourfold from control (no en- 
oxacin) to the 400 mg enoxacin dose level. Similarly, 
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the mean amount of 1,3-MU recovered in urine fell 
fourfold from control to the 400 mg enoxacin dose level. 
The mean amount of 1-MU recovered in urine fell by 
more than threefold from control to the 400 mg en- 
oxacin dose level. 
Other studies'3 conducted on the theophylline- 
enoxacin interaction report that therapeutic doses of 
enoxacin will increase plasma theophylline levels two- 
fold to threefold. Our study confirms this and indicates 
that the elevation is dose dependent. 
Finally, our results imply that the interaction is un- 
likely to become more significant when the daily dose 
of enoxacin exceeds 400 mg every 12 hours, because 
the change in oral clearance appeared to be asymptotic 
at the 400 mg enoxacin dose. Thus theophylline dosages 
will unlikely need to be decreased by more than 66% 
when enoxacin dosage exceeds 400 mg twice daily. 
We will subsequently report results of another study 
in which the onset and disappearance of the enoxacin- 
theophylline interaction was studied. 
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